Gas Offers Hope Against Superbug Pneumonia

In intensive care units, drug-resistant pneumonia, especially from Pseudomonas aeruginosa, poses a significant challenge due to limited treatment options.

Researchers at Massachusetts General Hospital have investigated the use of inhaled nitric oxide, a gas naturally produced by the body and used clinically at low doses, at much higher concentrations.

A study published in Science Translational Medicine utilized a large-animal ICU model involving pigs infected with multidrug-resistant P. aeruginosa. One group received high-dose inhaled nitric oxide (300 ppm) for short periods, while the control group received standard care.

The treated group demonstrated a 99% reduction in lung bacterial counts, improved oxygenation, and better lung function. Researchers suggest the gas may help restore chemical signaling in the lungs, improving oxygen transfer and reducing the need for certain medications.

Initial safety assessments in healthy human volunteers showed that inhaling nitric oxide at 300 ppm for five days resulted in only brief, minor increases in methemoglobin levels, staying well below safety thresholds. The feasibility of administering this high dose was also demonstrated in two critically ill ICU patients.

However, experts advise caution. While promising, the long-term durability of antimicrobial effects and potential toxic effects of nitric oxide require further investigation. Significant technical and operational hurdles must also be overcome to implement this therapy in most hospitals, which are not currently equipped for such high concentrations.

Future clinical efficacy trials are necessary to confirm patient outcome improvements, with the gas intended to supplement, not replace, standard ICU care.